10-Q · April 13, 2026
Lexaria reported Q2 revenue of $20,000 (down from $174,000 a year ago) and a narrower loss per share of $(0.06) versus $(0.15) a year ago. Management raised $6.52 million of equity proceeds in the six-month period,…
Earnings analysis · 10-Q
LEXX earnings analysis
Filed July 13, 2026 · Our reading of the company's report
The latest report
Lexaria reported a significant decline in revenue for Q2 2026, with total revenue decreasing to $20,000 from $531,923 a year earlier. Despite the revenue drop, the company achieved a narrower loss per share of -$0.06…
Read full summary
Lexaria reported a significant decline in revenue for Q2 2026, with total revenue decreasing to $20,000 from $531,923 a year earlier. Despite the revenue drop, the company achieved a narrower loss per share of -$0.06 compared to -$0.15 in the prior year. Operating expenses were reduced, reflecting operational efficiencies, but substantial doubt about the company's ability to continue as a going concern remains.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.06
What stood out
-
Revenue Decline Year-Over-Year
Q2 revenue fell drastically by $511,923, down to $20,000 from $531,923 a year ago.
-
Narrowed EPS Loss
The diluted EPS loss improved to -$0.06 from -$0.15 year-over-year.
-
Decreased Operating Expenses
R&D expenses decreased by $4.24 million compared to last year, improving overall operating margins.
-
Improved Cash Position
Cash increased by $1.67 million in the nine months ended May 31, 2026, from the prior year.
-
Equity Financing Boost
Raised approximately $6.5 million in net proceeds from securities sales in 2026.
-
Positive Results in R&D
Positive findings reported from clinical studies using DehydraTECH technology.
What to watch
-
Revenue Collapse
Total revenue decreased by 96.2% year-over-year, raising red flags about operational sustainability.
-
Substantial Doubt About Going Concern
Management has indicated there is substantial doubt regarding the company’s ability to continue operations for the next 12 months.
-
Negative Operating Margin
The operating margin remained significantly negative at -7259.5% in Q2 2026.
Management's outlook
Management anticipates that cash resources will be sufficient to fund operations through the first quarter of fiscal year 2027, but existing cash will not meet long-term obligations.
Earlier filings 4
10-Q · January 13, 2026
Lexaria reported zero revenue for the three months ended November 30, 2025 (vs. $183,923 in the prior-year quarter) while reducing its net loss to $1,595,007 and narrowing diluted loss per share to $(0.07) from $(0.16).…
10-Q · July 14, 2025
Lexaria reported Q3 revenue of $174,000 (100% gross margin), up from $84,000 in the year‑ago quarter and flat sequentially. Losses widened: GAAP net loss was $(3,790,606) for the quarter (basic and diluted loss per…
10-Q · April 14, 2025
Lexaria reported Q2 revenue of $174,000 (vs. $145,000 LYQ), beating the quarter estimate and delivering 100% gross margin, but losses widened as operating expenses jumped. EPS was a loss of $(0.15) (vs. $(0.06) LYQ) and…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.